Details for New Drug Application (NDA): 208799
✉ Email this page to a colleague
The generic ingredient in AIRDUO RESPICLICK is fluticasone propionate; salmeterol xinafoate. There are twenty-nine drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the fluticasone propionate; salmeterol xinafoate profile page.
Summary for 208799
Tradename: | AIRDUO RESPICLICK |
Applicant: | Teva Pharm |
Ingredient: | fluticasone propionate; salmeterol xinafoate |
Patents: | 28 |
Pharmacology for NDA: 208799
Mechanism of Action | Adrenergic beta2-Agonists Corticosteroid Hormone Receptor Agonists |
Suppliers and Packaging for NDA: 208799
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
AIRDUO DIGIHALER | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799 | NDA AUTHORIZED GENERIC | Teva Pharmaceuticals USA, Inc. | 0093-3607 | 0093-3607-82 | 1 POUCH in 1 CARTON (0093-3607-82) / 1 INHALER in 1 POUCH / 60 POWDER, METERED in 1 INHALER |
AIRDUO RESPICLICK | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799 | NDA AUTHORIZED GENERIC | Teva Pharmaceuticals USA, Inc. | 0093-3607 | 0093-3607-82 | 1 POUCH in 1 CARTON (0093-3607-82) / 1 INHALER in 1 POUCH / 60 POWDER, METERED in 1 INHALER |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INHALATION | Strength | 0.055MG/INH;EQ 0.014MG BASE/INH | ||||
Approval Date: | Jan 27, 2017 | TE: | RLD: | Yes | |||||
Regulatory Exclusivity Expiration: | Jan 9, 2025 | ||||||||
Regulatory Exclusivity Use: | PEDIATRIC EXCLUSIVITY | ||||||||
Regulatory Exclusivity Expiration: | Jul 9, 2024 | ||||||||
Regulatory Exclusivity Use: | REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Nov 18, 2031 | Product Flag? | Substance Flag? | Delist Request? | Y |
Expired US Patents for NDA 208799
Complete Access Available with Subscription